Toft Group Completes Senior Vice President Search for Oncimmune Holdings plc (AIM: ONCL) in Nottingham, UK

Oncimmune Holdings plc (AIM: ONC.L), a leading early cancer detection company developing and commercialising its proprietary EarlyCDT® platform technology, announced the appointment of Shane Smith as Senior Vice President, Market Access & Reimbursement Oncimmune (USA).

Shane is a commercial leader with more than 15 years’ experience within market access, reimbursement and sales management. He has extensive knowledge of the US market and a proven track record in sales force development, training, government accounts, Managed Care Organisations and laboratory contracting. Shane is highly experienced in molecular diagnostic contracting with national, regional and local health sales plans, as well as reference laboratories and hospital systems of all sizes. In addition, he has successfully managed several high dose immunotherapy centres focused on oncology. His experience also covers recruitment, managing and developing field based talent, conducting coaching, training, and providing directional leadership for both diagnostic and therapeutic products.

Robin Toft, President and CEO of Toft Group said: “We are thrilled to have worked with the senior leadership of Oncimmune Holdings plc, and congratulate Shane on his new role. We have every confidence that he will make an exceptional contribution to the company’s continued success.”

Most recently, Shane was Vice President, Market Access & Reimbursement, Lineagen, Inc. in Salt Lake City, UT where he focused on coverage and value-based reimbursement for Lineagen’s portfolio. He developed and executed Lineagen’s market access and payor strategies for its optimized chromosomal microarray test and its gene sequencing test. Prior to Lineagen, Shane led Market Access, Payer Markets, & Reimbursement for KEW Group where he managed reimbursement contracts and billing policies, working with organisations, business partners, institutions, commercial and government payors to establish coverage and value-based reimbursement for their proprietary next-generation sequencing solid tumor gene test. Earlier in his career, Shane held multiple sales roles with Prometheus Laboratories as well as Novartis Pharmaceuticals Corp.

Geoffrey Hamilton-Fairley, CEO of Oncimmune, said: “I am delighted to welcome Shane to Oncimmune. His appointment means that we have now completed the management team development we outlined at the time of our IPO. With Shane’s wealth of experience adding to our already strong team, I am even more confident we have the necessary sales structure in place to fully exploit our EarlyCDT®-Lung test as well as looking to develop and bring to market other diagnostic tests from across the EarlyCDT® platform.”

Commenting on his appointment, Shane Smith said: “EarlyCDT®-Lung has the potential to detect cancer up to four years earlier than other methods and I hope to use my previous experience in commercialising multiple diagnostic devices to make sure that this test becomes commercially available to as many patients and payors as possible. I am excited about my future at Oncimmune and look forward to sharing in its success.”

About Toft Group Executive Search

Toft Group Executive Search is “Changing the Future of Medicine, One Relationship at a Time” and we take pride in the fact that our work helps our clients accelerate getting novel products to market. We are a global retained executive search firm that is 100% dedicated to life sciences & healthcare industries. Our customers include biotech, pharmaceutical, medical device, digital health, and diagnostic companies. With offices in San Francisco, San Diego, and Boston, we assist a wide range of local, national and international companies – from venture backed start-ups to Fortune 500 corporations.

About Oncimmune

Oncimmune is a leading early cancer detection company developing and commercialising its proprietary EarlyCDT® platform technology. Oncimmune has pioneered the development of autoantibody tests that can detect cancer up to four years earlier than other methods and can be applied to a very wide range of solid tumour types. The Company’s first product, EarlyCDT®-Lung, was launched in 2012, as a CLIA test in the USA and since then over 150,000 commercial tests have been sold. EarlyCDT®-Lung is available through physicians in the US and also privately in the UK and other regions. EarlyCDT®-Lung is being used in the largest ever randomised trial for the early detection of lung cancer using biomarkers, the National Health Service (NHS) Scotland ECLS study of 12,000 high-risk smokers. EarlyCDT® tests for liver and ovarian cancer are in development.

Toft Group Completes Executive Search for Agilent Technologies, Inc. (NYSE: A) in Santa Clara, CA

Executive search firm Toft Group has placed Dr. David Shack as the Global Director – Diagnostics and Genomics Engineering for Agilent Technologies in Santa Clara, CA. Dr. Shack is a technology and engineering leader offering 20+ years of industry experience. He previously spent the past 11 years with BD Biosciences, most recently with their Genomics division as Senior Director of Engineering. He holds a PhD and Master’s in Mechanical Engineering from Stanford University.

About Agilent Technologies, Inc.

Agilent Technologies Inc. (NYSE: A), a global leader in life sciences, diagnostics and applied chemical markets, is the premier laboratory partner for a better world. Agilent works with customers in more than 100 countries, providing instruments, software, services and consumables for the entire laboratory workflow. The company generated revenues of $4.20 billion in fiscal 2016 and employs about 12,500 people worldwide.

Toft Group Completes Executive Search for Specific Technologies in Mountain View, CA

Executive search firm Toft Group has placed Mr. Elias Fayad as Vice President of Software at Specific Technologies in Mountain View, CA. He has been leading software development, data mining and visualization product development projects for almost 20 years. He previously served as the Director of Software Engineering, Instrument Control & Customer Applications for Pacific Biosciences. He holds a Master’s in Biomedical Engineering from The Ohio State University.

About Specific Technologies

Specific’s industry-leading team is developing clinically proven, regulated in vitro diagnostic systems based on a low cost and labor-saving sensor technology that enables rapid detection, Gram status and species identification (ID) of microorganisms directly in the blood culture bottle. The Company’s patented chemical fingerprinting technology combines detection and ID steps into a single, hands-free step, enabling faster time to result, laboratory costs savings and labor saving that speed time from sample-to-answer. Leveraging the same innovative technology, Specific is also developing an antibiotic susceptibility testing (AST) paradigm that would represent a new level of speed, ease of use and affordability in the all-important phenotypic determination of antibiotic susceptibility. These two systems will work in concert to offer a modernized next-generation workflow for the microbiology laboratory.

Toft Group Completes Executive Search for Axovant Sciences (NYSE: AXON) in New York, NY

Executive search firm Toft Group has placed Mr. Timothy King as Senior Director, Market Access for Axovant Sciences in New York, NY. Mr. King’s career spans 20 years of marketing leadership within the pharmaceutical industry. He most recently served as SVP of Strategic Services for Spark Health, LLC. Prior, he spent 13 years with Boehringer Ingelheim, his last role as Director of Biosimilar Marketing supporting market access for their lead immunology candidate. He earned an MBA from the University of Chicago.

About Axovant Sciences

Axovant Sciences Ltd. is a clinical-stage biopharmaceutical company focused on developing novel therapeutics to address the cognitive, functional and behavioral aspects of dementia and related neurological disorders.

Toft Group Completes Executive Search for Agilent Technologies, Inc. (NYSE: A) in Santa Clara, CA

Executive search firm Toft Group has placed Mr. Jeffrey Heimburger as the Senior Director of Marketing, Genomics for Agilent Technologies in Santa Clara, CA. He offers 20 years of marketing leadership experience, most recently serving as a strategy consultant for mobile enterprise start-up ventures and private equity firms.

About Agilent Technologies, Inc.

Agilent Technologies Inc. (NYSE: A), a global leader in life sciences, diagnostics and applied chemical markets, is the premier laboratory partner for a better world. Agilent works with customers in more than 100 countries, providing instruments, software, services and consumables for the entire laboratory workflow. The company generated revenues of $4.20 billion in fiscal 2016 and employs about 12,500 people worldwide.

Toft Group Completes Executive Search for EvoFem Biosciences, Inc. in San Diego, CA

Evofem Logo. (PRNewsFoto/Evofem)

Executive search firm Toft Group has placed Dr. Craig Audet as the SVP Regulatory Affairs and Quality Assurance for EvoFem Biosciences, Inc., in San Diego, CA. Dr. Audet is a pharmaceutical industry executive specializing in regulatory affairs, compliance drug and device development and marketing. He most recently served at Arena Pharmaceuticals as Senior Vice President, Operations & Head of Global Regulatory Affairs. He holds a BS in Biology/Pre-med from Boston College and a PhD in Public Health from Walden University.

About EvoFem Biosciences, Inc.

Evofem Biosciences™ is a biotechnology company focusing on developing innovative reproductive health products for women in every global market. Evofem Biosciences develops and markets products that are woman-controlled, non-invasive and rapidly reversible. Women need access to effective products that are well suited to their lifestyle and consistent with their core values.

Toft Group Completes Executive Search for Akili Interactive Labs in Boston, MA

Executive search firm Toft Group has placed Mr. Jeffrey Abraham as the Vice President of Market Access at Akili Interactive Labs in Boston, MA. Jeffrey has over 10 years’ experience in healthcare services/operations, market access, reimbursement, and HEOR. Jeffrey has worked both on the industry and consulting side of pharmaceuticals, medical devices, and diagnostics. His previous experience includes global work in the US, EU, and select APAC markets, covering 30 different products. Most recently he served as the Value Development Lead for The Medicines Company and their surgery/perioperative products. He was responsible for a value and evidence based approach to access and commercialization. He graduated from Boston University with a Bachelor of Health Sciences, Master of Science in Physical Therapy, and a Master of Business Administration.

About Akili Interactive Labs

Akili is building clinically validated cognitive therapeutics, assessments and diagnostics that look and feel like high-quality video games. Leveraging medical-grade science and consumer-grade software technology, the company is seeking to produce a new type of healthcare product that is both highly-effective and highly-engaging. The company was founded by PureTech Health, together with leading neuroscientists and game designers. Akili has garnered investment from Shire PLC and has strategic partnerships with Pfizer Inc. and Autism Speaks.

Toft Group Completes Executive Search for Genalyte, Inc., in San Diego, CA

Executive search firm Toft Group has placed Ms. Kristin Blitsch as Director Product Marketing, Cloud at Genalyte, Inc., in San Diego, CA. She brings 15 years of experience to her new role in global product lifecycle management for capital equipment, software and various products. Kristin previously managed Critical Care at Edwards Life Sciences including development of hemodynamic monitoring system connectivity products that interfaces via HL7 with hospital information technology, a cloud server, and integration engines. She earned her MBA from UCSD.

About Genalyte, Inc.

Genalyte’s vision is to transform the doctor-patient relationship by bringing the doctor, the patient, and the lab together to provide results when they matter: Now. Genalyte’s platform is being designed with the goal of providing test results from a whole blood sample within fifteen minutes in the physician’s office. Providing diagnostic results at the time and place they are needed – when the patient is sitting in front of the doctor – has the potential to empower physicians, improve quality of care for patients, and reduce resource utilization across the healthcare system. Genalyte’s technology is based on a proprietary silicon biosensor design that is currently in use by pharmaceutical companies, contract research organizations and academic researchers.

Toft Group Completes Senior Vice President of Strategy and Corporate Development Search for Agilent Technologies Inc. in Santa Clara, CA

Agilent Technologies Inc., (NYSE: A) today announced that Samraat “Sam” Raha has been named Senior Vice President of Strategy and Corporate Development, reporting to Agilent President and CEO Mike McMullen.

Raha will serve as strategic lead and advisor to the CEO and executive team in developing Agilent’s overall growth strategy, including leading its mergers and acquisitions plans globally.

“Sam shares our vision of the marketplace and knows what it takes to drive new growth,” McMullen said. “He joins us with an impressive portfolio of relevant experience in general and operational management, marketing and strategy that builds on a foundation of life sciences knowledge. He will be an excellent addition to our executive team.”

Raha joins Agilent from Illumina Inc. where he most recently served as Vice President of Global Marketing. He was responsible for product management, clinical and corporate marketing, marketing operations and strategy. He also led the successful go-to-market strategy and launch of many impactful products, including multiple sequencing systems and consumables.

Robin Toft, President and CEO of Toft Group said: “Agilent Technologies is an exciting company with an incredibly strong leadership team. Sam will add great value to the organization, and will be a strong contributor to the future growth of the company.”

Prior to his years at Illumina, Raha was Vice President and General Manager of the genomic assays business unit at Life Technologies, responsible for the TaqMan™ franchise and next-generation qPCR instruments and solutions.

Before that Raha was CEO of Joby Inc., a startup that has since become a leading seller of camera accessories.

“I am delighted to be returning to Agilent, where I spent several years in my early career,” Raha said. “Agilent clearly has fantastic growth potential. The opportunity to lead its overall growth strategy and build new partnerships to further its success in high-growth markets is truly exciting, and I am eager to begin leading these efforts.”

About Toft Group Executive Search

Toft Group Executive Search is “Changing the Future of Medicine, One Relationship at a Time” and we take pride in the fact that our work helps our clients accelerate getting novel products to market. We are a global retained executive search firm that is 100% dedicated to life sciences & healthcare industries. Our customers include biotech, pharmaceutical, medical device, digital health, and diagnostic companies. With offices in San Francisco, San Diego, and Boston, we assist a wide range of local, national and international companies – from venture backed start-ups to Fortune 500 corporations.

About Agilent Technologies Inc.

Agilent Technologies Inc. (NYSE: A), a global leader in life sciences, diagnostics and applied chemical markets, is the premier laboratory partner for a better world. Agilent works with customers in more than 100 countries, providing instruments, software, services and consumables for the entire laboratory workflow. The company generated revenues of $4.20 billion in fiscal 2016 and employs about 12,500 people worldwide.

Toft Group Completes Executive Search for Northway Biotech in San Francisco, CA

Executive search firm Toft Group has placed Ms. Tamara Smith as Vice President, Sales and Business Development at Northway Biotech in San Francisco, CA. She offers 20 years of strategic planning, complex negotiations, and extensive knowledge of bioprocessing operations in business development and sales, project management roles within the biotechnology space. She joined Northway from CMC Biologics where she held the role of Sr. Director of Business Development.

About Northway Biotech

Northway Biotech is a startup affiliate of Biotechpharma, a contract development and manufacturing organization (CDMO), supporting clients world-wide. Biotechpharma performs different projects at any stage, starting from cell line construction and process development up to cGMP production of biopharmaceutical products.